FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME Scientific Advisory Board Poxel receives guidance from a distinguished Scientific Advisory Board composed of prominent scientists in the fields of diabetes, metabolism and drug development. Prof. Cliff Bailey, PhD, FRCP(Edin), FRCPath Head of Diabetes Research and Professor of Clinical Science Aston University, Birmingham, England Prof. Ele Ferrannini, MD Professor of Medicine, Honorary Research Associate, Nation Research Council (CNR), Institute of Clinical Physiology, Pisa, Italy Prof. John E. Gerich, MD University of Rochester School of Medicine, Rochester, NY, USA Prof. Silvio E. Inzucchi, MD Professor of Medicine (Endocrinology), Clinical Director, Section of Endocrinology, Yale School of Medicine, New Haven, USA Prof. Masato Kasuga President, National Center for Global Health and Medicine, Tokyo, Japan Prof. Harold E. Lebovitz, MD, FACE Professor of Medicine, Division of Endocrinology and Metabolism/Diabetes State University of NY, Health Sciences Center, Brooklyn, USA Prof. Michael Roden, MD Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Düsseldorf, Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Düsseldorf, German Center for Diabetes Research (DZD e.V.), Partner Düsseldorf, Germany Prof. Guntram Schernthaner, MD Head of the Department of Medicine 1, Rudolfstiftung Hospital, Vienna, Austria Prof. Kohjiro Ueki Director, Diabetes Research Center, the National Center for Global Health and Medicine, Tokyo, Japan Prof. Hirotaka Watada Professor, Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact

FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME About Us We are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, currently focused on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for type 2 diabetes. Our lead compound, Imeglimin, has completed Phase 2 clinical development for type 2 diabetes in the EU and US, achieving proof-of-concept in two Phase 2a clinical trials and met primary and secondary endpoints in a Phase 2b dose-ranging trial. © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact